

## Special Issue

# Cancer Nanomedicine—From the Bench to the Bedside

### Message from the Guest Editor

As we all know, finding efficient non-invasive imaging systems to be used in diagnosing cancer and novel effective anticancer therapies are two urgent and still unresolved problems. Nanotechnology-based therapeutic systems exhibit major benefits with respect to conventional tracers and active agents, including higher imaging resolution, improved half-life, more efficient tumor targeting, enhanced therapeutic action, drug resistance bypass, and reduced side effects.

This Special Issue welcomes submission on nanosystems for cancer imaging/anticancer nanotherapeutics with one or more of the following aspects:

- Computer-assisted design, synthesis, and optimization of new covalent/self-assembled chemical entities as cancer nanomedicines and/or nanosystems carrying anticancer agents;
- Physicochemical and structural characterization;
- In vitro and in vivo studies, including cellular uptake and localization of the compounds, controlled release, mechanism of the anticancer activity, characterization and modeling of the PK/PD relationship, etc.

---

### Guest Editor

Prof. Dr. Sabrina Pricl

Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS),  
Department of Engineering and Architecture, University of Trieste,  
34127 Trieste, Italy

---

### Deadline for manuscript submissions

closed (31 August 2021)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

**Impact Factor 5.5**  
**CiteScore 10.0**  
**Indexed in PubMed**



[mdpi.com/si/35915](https://mdpi.com/si/35915)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).